M Cottler Fox

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease
    D Przepiorka
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 92:4066-71. 1998
  2. ncbi request reprint Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
    D Przepiorka
    Department of Blood and Marrow Transplantation, University of Texas, M D Anderson Cancer Center, Houston, USA
    Ann Oncol 10:527-32. 1999
  3. ncbi request reprint Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
    D Przepiorka
    Departments of Blood and Marrow Transplantation, Biomathematics, Laboratory Medicine and Pathology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 94:1465-70. 1999
  4. ncbi request reprint Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
    D Przepiorka
    Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX 77030, USA
    Blood 95:83-9. 2000
  5. ncbi request reprint Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1
    D Przepiorka
    Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 6:190-7. 2000
  6. ncbi request reprint Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors
    D Przepiorka
    Baylor College of Medicine, Center for Cell and Gene Therapy, The University of Texas M D Anderson Cancer Center, 6565 Fannin Street, Houston, TX 77030, USA
    Blood 97:3405-10. 2001

Detail Information

Publications6

  1. ncbi request reprint A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease
    D Przepiorka
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 92:4066-71. 1998
    ..Antibodies targeting CD2 may be active in the treatment of acute GVHD, and evaluation of a humanized form of BTI-322 is warranted...
  2. ncbi request reprint Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
    D Przepiorka
    Department of Blood and Marrow Transplantation, University of Texas, M D Anderson Cancer Center, Houston, USA
    Ann Oncol 10:527-32. 1999
    ....
  3. ncbi request reprint Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
    D Przepiorka
    Departments of Blood and Marrow Transplantation, Biomathematics, Laboratory Medicine and Pathology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 94:1465-70. 1999
    ..GVHD prophylaxis and CD34(+) cell dose are independent risk factors for acute GVHD after allogeneic blood stem cell transplantation...
  4. ncbi request reprint Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
    D Przepiorka
    Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX 77030, USA
    Blood 95:83-9. 2000
    ..Daclizumab has substantial activity for the treatment of acute GVHD, and the second regimen evaluated is recommended for a controlled study. (Blood, 2000; 95:83-89)..
  5. ncbi request reprint Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1
    D Przepiorka
    Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 6:190-7. 2000
    ..02), but overall survival at day 180 did not differ significantly among the 3 groups. Tacrolimus does not abrogate the adverse impact of allele mismatching at HLA-DRB1 and HLA-DQB1 on the risk of moderate-to-severe acute GVHD...
  6. ncbi request reprint Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors
    D Przepiorka
    Baylor College of Medicine, Center for Cell and Gene Therapy, The University of Texas M D Anderson Cancer Center, 6565 Fannin Street, Houston, TX 77030, USA
    Blood 97:3405-10. 2001
    ..It can be concluded that the administration of filgrastim after allogeneic blood stem cell transplantation shortens the time to neutrophil recovery. (Blood. 2001;97:3405-3410)..